Analyst consensus rating
Ovid Therapeutics Analyst Rating: Strong Buy
Direct answer
Ovid Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.80.
Forecast evidence checked September 9, 2026.
Get free Ovid Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.75
- Average price target
- $5.80
- High price target
- $9.00
- Low price target
- $4.00
- Low target gap
- +45.5%
- Target upside
- +111.1%
- High target gap
- +227.3%
- Target range width
- 181.8%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ovid Therapeutics?
Ovid Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $5.80.
How far are Ovid Therapeutics's low and high targets from the recorded price?
The low target implies +45.5%, while the high target implies +227.3%.
How many analysts are included in Ovid Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Ovid Therapeutics's target upside or downside calculated?
The average target of $5.80 is divided by the recorded price of $2.75, then one is subtracted to produce +111.1%. This does not guarantee a future return.
When was Ovid Therapeutics's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.